Gabelli Comments on Pain Therapeutics, Inc.’s FY2021 Earnings (PTIE)

Pain Therapeutics, Inc. (NASDAQ:PTIE) – Investment analysts at Gabelli issued their FY2021 earnings estimates for shares of Pain Therapeutics in a research report issued to clients and investors on Thursday. Gabelli analyst K. Kedra expects that the brokerage will post earnings of ($0.35) per share for the year.

TRADEMARK VIOLATION WARNING: This piece of content was originally reported by Web Breaking News and is the property of of Web Breaking News. If you are reading this piece of content on another website, it was copied illegally and republished in violation of United States and international copyright & trademark law. The original version of this piece of content can be read at http://www.webbreakingnews.com/2017/03/26/gabelli-comments-on-pain-therapeutics-inc-s-fy2021-earnings-ptie.html.

Separately, Zacks Investment Research lowered Pain Therapeutics from a “buy” rating to a “hold” rating in a research report on Wednesday, November 30th.

Shares of Pain Therapeutics (NASDAQ:PTIE) opened at 0.86 on Friday. The company has a 50-day moving average of $0.65 and a 200 day moving average of $0.85. The firm’s market cap is $39.68 million. Pain Therapeutics has a 52-week low of $0.51 and a 52-week high of $3.00.

Institutional investors have recently bought and sold shares of the company. Gabelli Funds LLC raised its position in Pain Therapeutics by 9.4% in the fourth quarter. Gabelli Funds LLC now owns 175,000 shares of the biopharmaceutical company’s stock valued at $100,000 after buying an additional 15,000 shares during the last quarter. Acadian Asset Management LLC raised its stake in shares of Pain Therapeutics by 26.3% in the third quarter. Acadian Asset Management LLC now owns 443,430 shares of the biopharmaceutical company’s stock worth $444,000 after buying an additional 92,358 shares in the last quarter. Spark Investment Management LLC acquired a new stake in shares of Pain Therapeutics during the third quarter worth $119,000. Finally, BVF Inc. IL raised its stake in shares of Pain Therapeutics by 6.0% in the third quarter. BVF Inc. IL now owns 2,278,552 shares of the biopharmaceutical company’s stock worth $2,278,000 after buying an additional 128,639 shares in the last quarter. Institutional investors and hedge funds own 44.34% of the company’s stock.

Pain Therapeutics Company Profile

Pain Therapeutics, Inc is a biopharmaceutical company. The Company is focused on drug development efforts on disorders of the nervous system, such as chronic pain. The Company’s lead drug candidate, REMOXY, is an abuse-deterrent, oral formulation of oxycodone (CII). The Company’s other products is FENROCK.

5 Day Chart for NASDAQ:PTIE

Receive News & Ratings for Pain Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pain Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Nike Suspends Relationship with Maria Sharapova
Nike Suspends Relationship with Maria Sharapova
Rob Bironas Ex-Titans Kicker Dies in Car Crash
Rob Bironas Ex-Titans Kicker Dies in Car Crash
Ron Washington Leaves Texas Rangers Due to an Affair
Ron Washington Leaves Texas Rangers Due to an Affair
Jonathan Dwyer Falls in Line with Other Banned NFL Players
Jonathan Dwyer Falls in Line with Other Banned NFL Players
Tony Stewart Case Going to the Grand Jury
Tony Stewart Case Going to the Grand Jury
Oscar Pistorius “Blade Runner” Found Not Guilty of Murder
Oscar Pistorius “Blade Runner” Found Not Guilty of Murder


Leave a Reply

 
© 2006-2017 Web Breaking News.